Search
GFT14
go.drugbank.com/drugs/DB05061ExperimentalGFT14 is a new class of medicaction for treatment of cardiometabolic disease. … Orally absorbed GFT14 has absolutely no structural link with current treatments for dyslipidemia (statin or fibrate based).
Zilovertamab vedotin
go.drugbank.com/drugs/DB18457InvestigationalZilovertamab vedotin is an Antibody-drug conjugate (ADC) comprising an anti-ROR1 monoclonal antibody (UC-961), a proteolytically cleavable maleimidocaproyl-valine-citrulline-para-aminobenzoate linker (
Mephenytoin
go.drugbank.com/drugs/DB00532ApprovedWithdrawnMephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins.
Metixene
go.drugbank.com/drugs/DB00340ApprovedMetixene (or methixene) is a anticholinergic used as an antiparkinsonian agent.
Adrenomedullin
go.drugbank.com/drugs/DB19102InvestigationalAdrenomedullin is under investigation in clinical trial NCT06072118 (Adrenomedullin for CADASIL).
Categories: Compounds used in a research, industrial, or household settingD2C7 immunotoxin
go.drugbank.com/drugs/DB17540InvestigationalD2C7-IT is under investigation in clinical trial NCT04160494 (D2C7-IT With Atezolizumab for Recurrent Gliomas). … D2C7 immunotoxin (D2C7-IT) is an investigational dual-specific monoclonal antibody targeting EGFRwt and EGFRvIII with a genetically engineered form of the _Pseudomonas exotoxin_, PE38-KDEL.
Talnetant
go.drugbank.com/drugs/DB06429Investigationalantipsychotic drug for the treatment of schizophrenia. … Talnetant (SB-223,412) is a neurokinin 3 receptor antagonist developed by GlaxoSmithKline, which is being researched for several different functions, primarily for irritable bowel syndrome and as a potential
Crotalus scutulatus antivenin
go.drugbank.com/drugs/DB13891ApprovedCroFab is more specifically tailored for crotalids of North America and is less allergenic than whole immunoglobulin antivenoms [L2861]. … CROFAB (crotalidae polyvalent immune fab (ovine))is a sheep-derived antivenin used for the management of adult and pediatric patients with North American crotalid envenomation [FDA label], which includes
Anti-SARS-CoV-2 REGN-COV2
go.drugbank.com/drugs/DB15691Investigational[L14306] Clinical trials for this drug started on June 11, 2020. … Anti-SARS-COV-2 REGN-COV2 is a combination of novel antibodies designed by Regeneron for both the prevention and treatment of SARS-COV-2, the virus that causes COVID-19.
Categories: Experimental Unapproved Treatments for COVID-19CDX-301
go.drugbank.com/drugs/DB19293InvestigationalCDX-301 is under investigation in clinical trial NCT02129075 (A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma).